Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Novo Nordisk (NVO - Analyst Report) has a strong presence in the Diabetes Care market with one of the broadest diabetes portfolios in the industry. The company is working hard to develop its diabetes pipeline.

We note that Novo Nordisk’s Victoza, a once-daily human GLP-1 analogue, is one of the leading players in the type II diabetes market. The drug has performed well since its launch in 2010. Since Victoza’s launch, the GLP-1 market has expanded in the U.S. Novo Nordisk is the leader in the worldwide GLP-1 segment with approximately 70% of market share (in terms of value) at the end of the third quarter OF 2013, up from 66% in 2012. The drug witnessed sales growth of 28% in the first nine months of 2013. The company is looking to expand Victoza’s label.

To achieve this objective, Novo Nordisk recently filed marketing applications with the U.S. and EU regulatory bodies for Victoza 3 mg, in combination with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, or who are overweight with comorbidities.

We note that Victoza is already approved for improving blood sugar levels in adult type II diabetes patients. Revenues from Victoza were DKK 2.8 billion in the third quarter 2013, up 14% y/y (up 20% in local currencies).

Novo Nordisk has started a phase IV trial on Victoza comparing it with Sanofi’s (SNY - Analyst Report) Lyxumia in Oct 2013. This 26-week study will evaluate the efficacy and safety of Victoza versus Lyxumia treatment as an add-on to metformin in type II diabetes patients. 

Novo Nordisk carries a Zacks Rank #4 (Sell). Investors may consider companies like Enanta Pharmaceuticals, Inc. (ENTA - Snapshot Report) and Questcor Pharmaceuticals Inc. ((QCOR - Analyst Report)), both of which carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 24.83 +14.85%
BITAUTO HOLD BITA 35.20 +14.40%
E HOUSECHINA EJ 10.98 +9.15%
CANADIAN SOL CSIQ 27.02 +7.34%
KNIGHTSBRIDG VLCCF 12.46 +5.41%